Multicenter Study Evaluating the Relationship Between Perceived Daily Stress Level and Glycemic Level in Subjects With Type 1 Diabetes

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

125 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-04-22

Study Completion Date

2026-02-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Type 1 diabetes (T1D) affects around 200,000 people in France. The only treatment is insulin, administered either by multiple injections, by pump alone or, more recently, by automated insulin delivery systems (AIDs), which have resulted in a very significant improvement in glycaemic control and quality of life. These closed-loop (CL) devices are capable of effectively regulating the conventional factors associated with glycaemic disturbance, namely dietary intake and physical activity. However, they do not account of stress, which some subjects with T1D perceive as a major disrupter of their blood sugar levels. One of the reasons for this is undoubtedly that stress, unlike diet or physical activity, cannot be anticipated. Since stress is difficult to predict, it is also more difficult to study. Its onset, intensity, duration and progression are linked to the subject's experience, psychological state and environment. Not all patients respond to stress triggers in the same way. Some patients appear to be more reactive than others to these agents, particularly when they are exposed to them chronically or repeatedly, in an anxiety-provoking environment. This is known as chronic psychosocial stress, and it is this type of stress that seems to be most closely associated with glycaemic disturbance in subjects with T1D, most often in the form of hyperglycaemia and, more rarely, hypoglycaemia. However, there are no solid epidemiological or experimental data to support these observations.

The study we propose is a prospective multicentre clinical trial in 125 subjects with T1D treated with insulin pumps or multi-injections at 14 French university centres. Our aim is to evaluate the relationship between interstitial glucose levels measured by CGM and perceived stress, assessed 4 times a day, away from mealtimes in order to avoid the impact of dietary glycaemia, using a "stressometer". This stressometer is an application designed by CERITD that can be downloaded to the patient's smartphone and consists of an electronic visual analogue scale (VAS) on which the level of stress felt is evaluated quantitatively (continuous value between 0 and 10).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Development of Artificial Intelligence Tools for the Detection of Stress Markers and Consideration of Stress States in the Monitoring of Subjects With Type 1 Diabetes

NCT06985862

Diabetes Type 1

RECRUITING NA

National Epidemiological Study of the Possible Impact of Stress on Glycaemic Control in Patients With Type 1 Diabetes

NCT06365255

Diabetes Type 1

COMPLETED

Reducing Stress in Adolescents and Young Adults With Type 1 Diabetes to Improve Diabetes Care

NCT02760303

Type 1 Diabetes

COMPLETED NA

A Mind-Body Intervention for Diabetes Management: A Pilot Study

NCT04944264

Diabetes Mellitus Stress, Psychological Stress, Physiological

COMPLETED NA

Prevalence of Post Traumatic Stress Disorder Related to Diabetes Diagnosis or Severe Hypoglycaemia in Adult With Type 1 Diabetes

NCT05662657

Type 1 Diabetes

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Type 1

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Visual analog scale to measure stress levels

Group Type EXPERIMENTAL

Assess stress levels 4 times a day before meals (morning, noon and evening and at bedtime) using a visual analogue scale

Intervention Type BEHAVIORAL

In addition to stress assessment with the stress meter, patients will be fitted with a Continious Glucose Monitoring

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Assess stress levels 4 times a day before meals (morning, noon and evening and at bedtime) using a visual analogue scale

In addition to stress assessment with the stress meter, patients will be fitted with a Continious Glucose Monitoring

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient with a clinical diagnosis of type 1 diabetes of at least 1 year, as determined by the medical record;
* Patient aged at least 18 years;
* Patient treated with an external insulin pump for at least 2 months or with multi-injections;
* Patient with a smartphone compatible with iOS 15.0 or higher or Android 12.0 or higher;
* Patient with a smartphone with Bluetooth 5.0 or higher;
* Patient with HbA1c ≤ 10% with measurement ≤3 months;
* Patient with no psychiatric pathology that could interfere with the study;
* Patient having signed the free and informed consent form to participate in the study;
* Patient affiliated to the French Social Security system;
* Patient agreeing not to eat between meals for the duration of the study (except for hypoglycaemia and/or snacks during physical activity);
* Patient agrees to wear an Empatica EmbracePlus watch for the duration of the study and to charge it according to the device's requirements for recording data;
* Patient agreed to wear an OURA ring for the duration of the study and to recharge it as required by the device to enable data recording (patients at the CERITD centre only).

Exclusion Criteria

* Type 2 diabetic patient;
* Patient fitted with a closed loop (or artificial pancreas);
* Patient with any characteristic pathology that could interfere with the study (renal failure, unstabilised diabetic retinopathy, heart failure, heart attack within 6 months prior to inclusion, severe neuropathy, particularly autonomic neuropathy);
* Patients with a tendency to snack;
* Patients undergoing treatment with drugs known to significantly interfere with blood sugar levels or the adrenergic system, such as corticosteroids and beta-blockers;
* Patients undergoing atropine treatment (Hydroxyzine Chlorhydrate or Atarax®...), likely to modify the EDA (Electrodermal Activity) ;
* Patients with a known allergy to latex (watch EmbracePlus);
* Pregnant woman;
* Nursing woman;
* Persons deprived of their liberty by judicial or administrative decision, persons under psychiatric care;
* Persons under guardianship or trusteeship or subject to a legal protection measure
* Persons who are not affiliated to a social security scheme or are beneficiaries of such a scheme.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No